- Published on
Drug or Medical Technology? China’s Dual-Track Regulation of Cell and Gene Therapy under State Council Order No. 818
- Authors

- Name
- Vishal V
- @VishalVignesh_
Notes
Abstract
cell or gene therapy (CGT) is regulated as a drug or as a medical technology determines who approves it, on what evidence, and at what cost (3)
May 1, 2026, China’s Regulation on the Clinical Research and Translational Application Management of New Biomedical Technologies (State Council Order No. 818) took effect (3)
supplemented by three implementing instruments issued in April 2026 (3)
first track regulates CGT as a biologic under the National Medical Products Administration (NMPA) (3)